Table of Contents
DUBLIN, Ireland — Endo International plc is implementing a new management structure that will bring changes to its executive leadership and senior management team.
Plans call for Endo’s U.S. Branded Pharmaceuticals and U.S. Generics business units, as well as the company’s Branded Pharmaceutical R&D unit, to report directly to Rajiv De Silva, president and chief executive officer of Endo.
"Following the close of the Auxilium transaction, expected later this month, we have the opportunity to significantly accelerate the organic growth of our branded portfolio. The changes we are making are designed to streamline decision making and drive continued expansion of our branded products that we anticipate will deliver sustained growth," De Silva stated in announcing the changes on Friday. "This new structure will allow me to play a greater role in managing these important businesses as well as our branded R&D efforts, as we pursue organic growth opportunities for the company."
Endo said that with the proposed new structure, Don DeGolyer, chief operating officer for pharmaceuticals, is leaving the company to pursue other opportunities. DeGolyer is slated to step down effective March 1 and remain with the company until Aug. 1 as a special adviser to the CEO.
"I would like to recognize Don for his leadership and contributions during the critical transformation of Endo," De Silva commented. "During his tenure, we have exceeded financial targets in our pharmaceutical businesses, sharpened our R&D focus on near-term opportunities, enhanced our focus on organic growth drivers and integrated several accretive acquisitions. We are fortunate that Don leaves behind a strong team of professionals who have successfully managed our U.S. Branded business and the Qualitest business over the past several years. We wish Don continued success in his future endeavors."
With the close of the Auxilium transaction, Endo’s U.S. Branded Pharmaceuticals business will continue to be led by Brian Lortie, president of U.S. Branded Pharmaceuticals, reporting to De Silva.
In addition, Blaine Davis will become senior vice president and general manager of the newly created specialty pharmaceuticals business unit, reporting to Lortie. Davis previously was president of Endo Ventures Ltd. and senior vice president of corporate affairs.
Endo added that it expects to designate other senior leadership roles in the U.S. Branded Pharmaceuticals business before the close of the Auxilium acquisition.
In the U.S. Generics Business, Robert Rush, currently Endo’s senior vice president of finance is slated to become general manager of Qualitest on an interim basis effective March 1 while the company conducts a search for a permanent general manager. Rush will report to De Silva during the interim period.
Meanwhile, Susan Hall, Endo’s current chief scientific officer and global head of research and development and quality, will continue in her role, reporting to De Silva.
The company said it anticipates defining additional senior leadership roles in the Branded Pharmaceutical R&D organization given the expanded portfolio of development assets.
Upon the close of the Auxilium transaction, Keri Mattox, currently senior vice president of investor relations and corporate communications at Auxilium, will serve as senior vice president of investor relations and corporate affairs, reporting to Suky Upadhyay, executive vice president and chief financial officer at Endo.
Also, Robert Cobuzzi will become president of Endo Ventures Ltd., located in Dublin, Ireland, reporting to De Silva. Cobuzzi is currently senior vice president of R&D strategy and operations at Endo.
A global specialty health care company, Endo develops, manufactures, markets and distributes branded and generic pharmaceuticals, over-the-counter medications and medical device products. Its worldwide headquarters is in Dublin, Ireland, and its U.S. headquarters is located in Malvern, Pa.
